M&A Deal Summary

Edwards Acquires CardiAQ Valve Technologies

On August 26, 2015, Edwards acquired medical products company CardiAQ Valve Technologies for 400M USD

Acquisition Highlights
  • This is Edwards’ 7th transaction in the Medical Products sector.
  • This is Edwards’ largest (disclosed) transaction.
  • This is Edwards’ 7th transaction in the United States.
  • This is Edwards’ 3rd transaction in California.

M&A Deal Summary

Date 2015-08-26
Target CardiAQ Valve Technologies
Sector Medical Products
Buyer(s) Edwards
Deal Type Add-on Acquisition
Deal Value 400M USD

Target

CardiAQ Valve Technologies

Irvine, California, United States
CardiAQ Valve Technologies, Inc. is a developer of a transcatheter mitral valve replacement system.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Edwards

Irvine, California, United States

Category Company
Founded 1958
Sector Medical Products
Employees19,800
Revenue 6.0B USD (2023)
DESCRIPTION
Entrance to Edwards Lifesciences' corporate headquarters in Irvine, California.
Entrance to Edwards Lifesciences' corporate headquarters in Irvine, California.

Edwards is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. Edwards was founded in 1958 and is based in Irvine, California.


DEAL STATS #
Overall 10 of 15
Sector (Medical Products) 7 of 12
Type (Add-on Acquisition) 5 of 9
State (California) 3 of 4
Country (United States) 7 of 11
Year (2015) 1 of 1
Size (of disclosed) 1 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-10-10 Bmeye B.V.

Amsterdam, Netherlands

BMEYE B.V., a privately held Dutch company that specializes in the development of non-invasive technology for advanced hemodynamic monitoring. BMEYE's technology provides continuous, real-time information to clinicians and can be used in the surgical, intensive care, emergency room and cardiology settings.

Buy €33M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-11-28 Valtech Cardio

Yehuda, Israel

Valtech Cardio Ltd. is specializes in the development of innovative surgical and transcatheter valve repair and replacement devices for the treatment of the most prevalent heart valve diseases – mitral valve regurgitation (MR) and tricuspid valve regurgitation (TR).

Buy $340M